Top Stock Gainers: TJGC, Elastic, Quoin Pharmaceuticals, and SMST Stand Out

• TJGC Group Limited (NASDAQ: TJGC) gained 24.69% amid continued interest in its potential artificial intelligence and robotics licensing strategy.
• Elastic N.V. (NYSE: ESTC) surged 19.31% after reporting better-than-expected fiscal Q1 2027 results and raising its financial guidance.
• Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) advanced 18.72% following positive interim Phase 2/3 clinical data and a private placement financing package of up to $50 million.

Several individual stocks and specialized funds posted strong gains despite a modest decline in the broader market. TJGC Group Limited (NASDAQ: TJGC) rose 24.69% to $9.90, while Elastic, Reading International, Quoin Pharmaceuticals, and an inverse leveraged fund tied to Strategy also recorded substantial increases.

TJGC Group Limited (NASDAQ: TJGC) previously disclosed that it was negotiating a potential intellectual property licensing agreement with a robotics technology provider. The proposed agreement would give TJGC nonexclusive worldwide rights to commercialize certain artificial intelligence and robotics technologies in intelligent automation products.

However, this announcement was originally made on August 10 rather than on the day of the stock’s latest gain. The negotiations remain preliminary, and TJGC has warned that there is no assurance that a definitive agreement will be reached. Therefore, the stock’s move may also reflect speculative trading in addition to optimism about its potential technology expansion.

Elastic N.V. (NYSE: ESTC) rose 19.31% to $99.91 following stronger-than-expected fiscal Q1 2027 results. Revenue increased 15% year over year to $478 million, exceeding the approximately $470 million expected by analysts. Adjusted diluted earnings reached $0.70 per share, compared with expectations of approximately $0.58.

Elastic also issued stronger guidance. The search and data analytics company projected fiscal Q2 revenue of $486 million–$487 million and adjusted diluted EPS of $0.80–$0.82. It raised its full-year adjusted EPS outlook to $3.29–$3.37, supported by demand across its search, security, observability, and AI-related products.

Reading International, Inc. Class B (NASDAQ: RDIB) jumped 18.90% to $18.31, after trading as high as $24.00. No significant new company announcement was identified that clearly explained the latest RDIB move. The stock’s price action appeared largely momentum-driven and was likely amplified by the relatively small number of publicly traded Class B voting shares. This limited liquidity can result in unusually large price movements when trading volume increases.

In the biotechnology sector, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) climbed 18.72% to $6.12 after announcing positive interim results from its ongoing Phase 2/3 study of QRX003 for Netherton syndrome. Four of the first six participants completing 12 weeks of treatment achieved the targeted improvement in the primary endpoint, producing a statistically significant result.

Quoin also announced a private placement expected to provide approximately $30.8 million in upfront gross proceeds and up to an additional $19.2 million through the potential exercise of warrants. The company expects the financing, assuming all warrants are exercised, to fund operations into the second half of 2029.

The Defiance Daily Target 2X Short MSTR ETF (NASDAQ: SMST) increased 14.55% to $26.30. The leveraged inverse fund seeks to deliver -200% of the daily percentage change in shares of Strategy Inc. (NASDAQ: MSTR), formerly known as MicroStrategy, before fees and expenses.

SMST’s gain reflected a sharp decline in Strategy shares rather than a general indication of positive market sentiment. Because the fund resets daily, its performance over periods longer than one trading day can differ significantly from twice the inverse return of Strategy’s stock.

In summary, the session’s leading gains came from different catalysts: earnings and guidance at Elastic, clinical results and financing at Quoin, speculative technology interest at TJGC, momentum trading in Reading International’s Class B shares, and an inverse leveraged position against Strategy.